# Innocrin Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innocrin-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Durham, US
- Website: www.innocrinpharma.com
- Total disclosed funding: $28M
- Latest round: Series D (Apr 14, 2015)
- Investors on record: 6

## About

Innocrin Pharmaceuticals is a private biotechnology firm focused on developing innovative oral treatments to combat hormone-sensitive cancers, particularly prostate and breast cancer. Their lead product targets crucial biochemical pathways essential for cancer growth.Innocrin Pharmaceuticals was founded in 2004 in Durham, US, specializing in the development of therapies for hormone-dependent cancers. The company has not undergone significant changes in its business strategy and operates as an independent entity without reported subsidiaries. The firm's founder's details are not available. It has completed a total of 2 funding rounds, with its most recent being a Series D financing round in April 2015, where it raised USD 28.00 mn led by Eshelman Ventures, with participation from Novartis Venture Fund, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners, and A&B Equity Holdings. The total amount raised by the company stands at USD 28.00 mn.Innocrin Pharmaceuticals is engaged in the clinical development of novel oral inhibitors targeting the CYP17 lyase enzyme, focusing on conditions such as castration-resistant prostate cancer (CRPC) and advanced breast cancer. Its main product, seviteronel, is a dual-action CYP17 inhibitor and androgen receptor antagonist, distinguished by its ability to selectively inhibit CYP17 lyase without impacting mineralocorticoid or glucocorticoid synthesis. The company is conducting clinical studies in the United States and Europe to assess the efficacy and safety of seviteronel for treating both prostate cancer and estrogen receptor-positive (ER+) as well as triple-negative breast cancer (TNBC). The target clientele encompasses oncologists, healthcare providers, and patients affected by these severe medical conditions.Innocrin Pharmaceuticals' revenue model is founded on its clinical research activities and the forthcoming commercialization of seviteronel and related products. Revenue generation is projected through partnerships with healthcare institutions and direct sales following regulatory approvals. The clinical development phase includes financial transactions related to research contracts, grants, and potential collaborations with larger pharmaceutical companies for distribution and marketing rights. Once clinical trials are successfully completed and regulatory approvals obtained, pricing strategies will be implemented that correspond to the therapeutic value of its oncology innovations, enhancing the firm's foothold in the competitive oncology therapeutics market.The firm plans to continue focusing on the clinical development of seviteronel, with a strategy aimed at launching the product following successful trials and regulatory approval. Innocrin Pharmaceuticals is targeting expansion into additional European markets and potentially Asia by 2026. The recent Series D funding round of USD 28.00 mn will support the company's ongoing clinical trials and the establishment of partnerships for future commercialization efforts, ensuring a robust infrastructure for launching seviteronel in new markets.

## Funding rounds

- Series D, Apr 14, 2015, $28M — Intersouth Partners, Novartis Venture Fund, Lilly Ventures, Hatteras Venture Partners, Eshelman Ventures, A&B Equity Holdings

## Investors

- Intersouth Partners (https://capitalatlas.ai/funds/intersouth-partners) — Series D
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series D
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series D
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series D
- Eshelman Ventures (https://capitalatlas.ai/funds/eshelman-ventures) — Series D
- A&B Equity Holdings — Series D